Actualités

Moby summary of Arko Corp.'s Q2 2026 earnings call

Yahoo Finance host Jared Blikre and The Wealth Consulting Group Chief Market Strategist Talley Léger discuss market leadership shifting from tech concentration to diffusion, explaining why investors must take a 'leap of faith' on massive AI capital spending by tech hyperscalers like Alphabet (GOOG), Meta (META), and Microsoft (MSFT).

Moby summary of ACM Research, Inc.'s Q2 2026 earnings call

Axon's 33% revenue surge commands a 67x forward multiple, while Chewy's steady 6% growth trades at less than half that valuation.

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

Photonics and optics stocks got a big boost Friday in the wake of strong earnings and amid anticipation of a potential setback for overseas competition.

(Updates with market moves at the end of the day, and any other changes, if any.) The S&P 500 hit

In the health insurance arena, one company is both the undisputed leader and the most expensive ticket, forcing investors to decide if paying up for quality is a winning strategy.

A soaring valuation now faces a major execution test

A legal battle between Apple and OpenAI over the ChatGPT-maker's secretive device project escalated this week when the artificial intelligence (AI) developer called the iPhone-maker's allegations "baseless" and asked for the lawsuit's dismissal.  Apple sued OpenAI last month in San Jose, California, accusing the AI company of orchestrating a campaign to steal the iPhone maker's trade secrets via former employees as it tries to develop its own consumer hardware device.

On July 30, Apple Inc. (NASDAQ:AAPL) released its fiscal third-quarter 2026 report, and the company’s shares dropped as much as 10% in the sell-off. This was a striking reaction to a quarter that produced record earnings per share and beat Wall Street’s revenue estimates. The drop says less about what Apple just did and more […]

The S&P 500 Index ($SPX ) (SPY ) closed up +0.62% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.28%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.19%. September E-mini S&P futures (ESU26 ) rose +0.55%, and September E-mini Nasdaq futures...

Downward revisions make July's slowdown harder to dismiss

U.S. stocks rose Friday after July payroll data came in far weaker than expected, giving the Federal Reserve reason to hold off on raising interest rates next month.

The Walt Disney Company plans to evolve Disney+ from a video platform into an integrated fan ecosystem combining games, merchandise, and interactive experiences by spring 2027, as Chief Executive Officer Josh D’Amaro declared that the entertainment giant is “just playing...

GE Vernova's recent post-earnings dip is a good buying opportunity.

The Trade Desk shares crash on a broadly disappointing Q2 earnings release, but Citi analyst says TTD stock could tumble further moving forward.

CoreWeave is due to report earnings after the closing bell Tuesday, with traders expecting a sizable move in the cloud computing provider’s stock in the days that follow.

Weak traffic is forcing a sharper strategic reset

Tesla has several major advantages when competing in the robotaxi market.

Small caps are finally outrunning the S&P 500, but IWM holders are leaving something significant on the table. Two overlooked alternatives have quietly delivered both stronger returns and a 14% income stream from the same rally.

US equity indexes jumped this week amid gains in technology heavyweights and growing expectations of

The sell-off came after the buy-now-pay-later company reported second-quarter results on Thursday that topped estimates and raised full-year guidance.

US equity indexes ended higher Friday after a surprise drop in nonfarm payrolls boosted the odds the

Yahoo Finance Tech Editor discusses reports that OpenAI (OPAI.PVT) is developing a $300+ puck-sized smart home device designed to compete directly with Amazon (AMZN) Alexa and Google Home

(Updates with index/price moves, analyst comments and geopolitical news from the first paragraph.)

Fresh institutional interest arrives before a critical execution update

Strong profits remain, but the cycle is starting to shift

One trades at a growth premium with minimal debt; the other offers higher margins and cash flow but faces a major tax dispute.

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee...